Sentence examples for completion of primary therapy from inspiring English sources

From July 2001 to July 2011, 48 patients (mean age of diagnosis 58.1 years) who completed initial therapy for ovarian carcinoma with no known cancer recurrence who underwent concurrent PET/CT and serum CA-125 within 3 to 9 months of completion of primary therapy for ovarian carcinoma were identified from the radiology database (Table 1).

In an effort to improve the ability to detect small volume disease, we have evaluated the usefulness of N -acetylglucosamine:β1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.

For progression-free survival, time from completion of primary therapy to recurrence or death was recorded.

At 3 months after completion of primary therapy, the first follow-up visit was scheduled.

Recurrent disease was defined as progression in surgically treated women with no evidence of disease following completion of primary therapy.

Recurrence was defined as a regrowth of tumor at least 3 months after the completion of primary therapy.

Overall, this trial will inform and refine exercise guidelines to optimize recovery in breast and other cancer survivors following the completion of primary cytotoxic therapy.

Against this background, we designed the EXCITE trial, a randomized trial comparing the effects of supervised moderate-intensity to high-intensity aerobic training in women with operable breast cancer following the completion of primary adjuvant therapy.

After completion of primary cancer therapy, patients received subcutaneous injections of a standardized mistletoe extract preparation corresponding to a dose of approximately 5 ng mistletoe lectin twice weekly for 3 months.

Participants with invasive breast cancer or ductal carcinoma in situ were enrolled in the trial after completion of primary surgical resection of breast cancer, and after any indicated adjuvant chemotherapy and/or radiation therapy.

These long-term toxicities, or late effects, defined as 'unrecognised toxicities that are absent or subclinical at the end of therapy' can manifest as new diagnoses months to years after the completion of primary cancer treatment (Hewitt et al, 2006).